🎉 M&A multiples are live!
Check it out!

Agios Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Agios Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Agios Pharmaceuticals Overview

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.


Founded

2007

HQ

United States of America
Employees

488

Website

agios.com

Financials

LTM Revenue $40.7M

LTM EBITDA -$441M

EV

$740M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Agios Pharmaceuticals Financials

Agios Pharmaceuticals has a last 12-month revenue of $40.7M and a last 12-month EBITDA of -$441M.

In the most recent fiscal year, Agios Pharmaceuticals achieved revenue of $36.5M and an EBITDA of -$420M.

Agios Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Agios Pharmaceuticals valuation multiples based on analyst estimates

Agios Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $26.8M $36.5M XXX XXX XXX
Gross Profit $12.5M $23.9M XXX XXX XXX
Gross Margin 47% 66% XXX XXX XXX
EBITDA -$385M -$420M XXX XXX XXX
EBITDA Margin -1435% -1151% XXX XXX XXX
Net Profit -$232M -$352M XXX XXX XXX
Net Margin -864% -965% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Agios Pharmaceuticals Stock Performance

As of April 15, 2025, Agios Pharmaceuticals's stock price is $28.

Agios Pharmaceuticals has current market cap of $1.6B, and EV of $740M.

See Agios Pharmaceuticals trading valuation data

Agios Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$740M $1.6B XXX XXX XXX XXX $6.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Agios Pharmaceuticals Valuation Multiples

As of April 15, 2025, Agios Pharmaceuticals has market cap of $1.6B and EV of $740M.

Agios Pharmaceuticals's trades at 18.2x LTM EV/Revenue multiple, and -1.7x LTM EBITDA.

Analysts estimate Agios Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Agios Pharmaceuticals and 10K+ public comps

Agios Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $740M XXX XXX XXX
EV/Revenue 20.3x XXX XXX XXX
EV/EBITDA -1.8x XXX XXX XXX
P/E 2.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Agios Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Agios Pharmaceuticals Valuation Multiples

Agios Pharmaceuticals's NTM/LTM revenue growth is 99%

Agios Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Agios Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Agios Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Agios Pharmaceuticals and other 10K+ public comps

Agios Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 36% XXX XXX XXX XXX
EBITDA Margin -1151% XXX XXX XXX XXX
EBITDA Growth 9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1052% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 825% XXX XXX XXX XXX
Opex to Revenue 1255% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Agios Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Agios Pharmaceuticals M&A and Investment Activity

Agios Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Agios Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Agios Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Agios Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Agios Pharmaceuticals

When was Agios Pharmaceuticals founded? Agios Pharmaceuticals was founded in 2007.
Where is Agios Pharmaceuticals headquartered? Agios Pharmaceuticals is headquartered in United States of America.
How many employees does Agios Pharmaceuticals have? As of today, Agios Pharmaceuticals has 488 employees.
Who is the CEO of Agios Pharmaceuticals? Agios Pharmaceuticals's CEO is Mr. Brian Goff.
Is Agios Pharmaceuticals publicy listed? Yes, Agios Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Agios Pharmaceuticals? Agios Pharmaceuticals trades under AGIO ticker.
When did Agios Pharmaceuticals go public? Agios Pharmaceuticals went public in 2013.
Who are competitors of Agios Pharmaceuticals? Similar companies to Agios Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Agios Pharmaceuticals? Agios Pharmaceuticals's current market cap is $1.6B
What is the current revenue of Agios Pharmaceuticals? Agios Pharmaceuticals's last 12-month revenue is $40.7M.
What is the current EBITDA of Agios Pharmaceuticals? Agios Pharmaceuticals's last 12-month EBITDA is -$441M.
What is the current EV/Revenue multiple of Agios Pharmaceuticals? Current revenue multiple of Agios Pharmaceuticals is 18.2x.
What is the current EV/EBITDA multiple of Agios Pharmaceuticals? Current EBITDA multiple of Agios Pharmaceuticals is -1.7x.
What is the current revenue growth of Agios Pharmaceuticals? Agios Pharmaceuticals revenue growth between 2023 and 2024 was 36%.
Is Agios Pharmaceuticals profitable? Yes, Agios Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.